TOTAL: $M54.0

Year to Date: $589.33M

Company
(Symbol)#*

Partner
(Country)

Amt.
(M)

Triggering
Event

Details (Date)


Cardiome
Pharma Corp.
(Canada; CRME)

Astellas Pharma US Inc.

$10

Milestone payment

Triggered by Astellas' resubmission of the NDA with the FDA seeking approval of the intravenous formulation of vernakalant hydrochloride for the acute conversion of atrial fibrillation (12/18)

Cerus Corp.
(CERS)

BioOne Corp. (Singapore)

$5

Milestone payment

Triggered by CE mark regulatory approval for the Intercept Blood System for plasma in Europe; Baxter Healthcare Corp. got $0.5M of the payment; another $5M milestone was expected in January (12/26)

Isis
Pharmaceuticals
Inc.
(ISIS)

iCo Therapeutics Inc. (Canada)

ND

Milestone payment

Triggered by iCo's filing of an IND to begin trials of iCo-007 for treating eye diseases (12/21)

Isis
Pharmaceuticals
Inc.
(ISIS)

Merck & Co. Inc.

$1

Milestone payment

Triggered by Merck's initiation of clinical development of a compound discovered in their funded research collaboration (12/5)

Micromet Inc.
(MITI)

Serono SA (Switzerland; NYSE:SRA)

$10

Milestone payment

Triggered by completion of two single-agent Phase II trials of adecatumumab (MT201) in metastatic breast and prostate cancers (12/4)

Neurocrine Biosciences Inc. (NBIX)

GlaxoSmithKline plc (UK)

$8

Milestone payment

Triggered by GSK's initiation of Phase II trials of a corticotropin releasing factor R1 receptor antagonist in social anxiety disorder and irritable bowel syndrome (12/20)

Targacept
Inc.
(TRGT)

AstraZeneca plc (UK)

$20

Milestone payment

Triggered by AstraZeneca's decision to continue development of AZD3480 (TC-1734) in Alzheimer's disease and cognitive deficits in schizophrenia (12/27)


Notes:

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

Currency conversions are based on exchange rates at the time of the deal.

ND = Not disclosed.

NYSE = New York Stock Exchange.

No Comments